MEPHYTON by Bausch + Lomb is clinical pharmacology mephyton tablets possess the same type and degree of activity as does naturally-occurring vitamin k, which is necessary for the production via the liver of active prothrombin (factor ii), proconvertin (factor vii), plasma thromboplastin component (factor ix), and stuart factor (factor x). Approved for the following coagulation disorders which are due to faulty formation of factors ii, interference with vitamin k activity. First approved in 1955.
Drug data last refreshed 5h ago · AI intelligence enriched 1w ago
MEPHYTON (phytonadione) is an oral vitamin K replacement therapy that restores hepatic synthesis of vitamin K-dependent clotting factors (II, VII, IX, X). It treats coagulation disorders caused by vitamin K deficiency or antagonism, with onset of action within 6–10 hours.
Long-established product with lifecycle maturity; brand team likely focused on market defense and managed care efficiency rather than growth initiatives.
CLINICAL PHARMACOLOGY Mephyton tablets possess the same type and degree of activity as does naturally-occurring vitamin K, which is necessary for the production via the liver of active prothrombin (factor II), proconvertin (factor VII), plasma thromboplastin component (factor IX), and Stuart factor…
Worked on MEPHYTON at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on MEPHYTON offers stability in a legacy product but limited growth trajectory; career value lies in mastering managed care negotiations, generic defense strategies, and efficient market operations. This role suits professionals seeking mature-market experience or transition into post-LOE lifecycle management rather than launch-driven innovation.